| Autor: |
Cardinale D; Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy (D.C.)., Lyon AR; Cardio-Oncology Service, Royal Brompton & Harefield NHS Foundation Trust and the National Heart & Lung Institute, Imperial College London, UK (A.R.L.)., López-Fernández T; Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain (T.L.-F.).; Cardiology Department, Quiron Pozuelo University Hospital, Madrid, Spain (T.L.-F.). |
| Abstrakt: |
Competing Interests: Disclosures Dr Cardinale reports consulting and speaker’s fees from Siemens Healthineers, Ipsen SpA, and Gilead Sciences, Inc not related to this work. Dr Lopez-Fernandez reports speaker and travel fees not related to this work from Philips, Janssen, Daiichi-Sankyo, Myocardial Solutions, Astra Zeneca, Pfizer, BMS, Beigene, Bayer. Dr Lyon is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology and the Royal Brompton Cardio-Oncology Centre of Excellence is supported by The Big Heart Foundation. He has received speaker, advisory board, or consultancy fees and research grants from Janssens-Cilag Ltd, Astellas Pharma, Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health, and Heartfelt Technologies Ltd. |
